Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anti-Infective R&D Ecosystem Getting Healthier, But Trials Remain

Executive Summary

FDA and other government agencies have successfully nurtured a healthy ecosystem to rebuild the antibiotics pipeline, and a new crop of antibiotics has now reached the pivotal stage of clinical trials. But the sponsors are largely small companies: can they survive in the highly constrained commercial market for serious infections?

You may also be interested in...



REPAIR Is Trying To Fix The Antibiotic Gap Left By Industry

As large biopharmaceutical companies continue to exit antibacterial R&D, investments by Novo Holding’s REPAIR Impact Fund and grants from CARB-X can push forward novel therapies for drug-resistant microbial infections.

Infectious Disease Companies Catch More Investors

Start-Up surveyed investments into, and exits by, private infectious disease-focused companies from 2013 through the first quarter of 2016, using data from Informa’s Pharma Intelligence's Strategic Transactions and Medtrack databases. Our review reveals an increasing amount of money going into these firms, especially those developing novel antibiotics against drug-resistant bacteria or with novel anti-infective drug development platforms.

AZ Spins Out Entasis To Tackle Resistant Infections

AstraZeneca has, after a long gestation, given birth to the antibiotic developer Entasis Therapeutics: in early July the biotech debuted with $40 million in funding from AZ alone, and a portfolio of the drugmaker’s early-stage antibiotic candidates. It emerges as the debate about incentivizing antibiotics R&D intensifies amid growing concerns about antibiotic-resistant bacteria.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel